Nemocnice Tabor a.s.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Nemocnice Tabor a.s. researchers are exploring innovative treatments for heart failure, focusing on patients with reduced or preserved ejection fraction and those unable to use standard mineralocorticoid receptor antagonists.
- New therapeutic approaches for acute decompensated heart failure
- Safety and efficacy of alternative mineralocorticoid receptor blockers
- Outcomes in patients intolerant to conventional heart failure medications
- Clinical strategies to reduce cardiovascular mortality
The program aims to improve survival and quality of life for individuals living with serious cardiac conditions through rigorous clinical evaluation.
Respiratory Tract Diseases
Studies at the site assess the impact of advanced inhaled therapies on Chronic Obstructive Pulmonary Disease, measuring both lung function and related heart health outcomes.
- Effectiveness of triple bronchodilator combinations
- Comparison of dual versus triple inhaled regimens
- Cardiopulmonary risk reduction in COPD patients
- Long‑term safety of high‑dose inhaler treatments
By linking respiratory and cardiac endpoints, the research seeks to deliver comprehensive care strategies for patients with overlapping lung and heart disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nemocnice Tabor a.s.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE | F. Hoffmann-La Roche AG | Phase III | Not Recruiting | Jul 2023 | Jul 2025 |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Finerenone | 2 | Unknown | 2024-10-08 | 2025-09-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.